Ascendis Pharma A/S (NASDAQ:ASND) Shares Bought by Stifel Financial Corp

Stifel Financial Corp grew its holdings in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 36.1% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 17,097 shares of the biotechnology company's stock after buying an additional 4,534 shares during the period. Stifel Financial Corp's holdings in Ascendis Pharma A/S were worth $2,354,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently made changes to their positions in the company. Wilmington Savings Fund Society FSB bought a new position in shares of Ascendis Pharma A/S during the 3rd quarter valued at approximately $30,000. Jones Financial Companies Lllp increased its position in Ascendis Pharma A/S by 394.0% during the fourth quarter. Jones Financial Companies Lllp now owns 247 shares of the biotechnology company's stock valued at $34,000 after acquiring an additional 197 shares during the last quarter. Blue Trust Inc. increased its position in Ascendis Pharma A/S by 415.2% during the fourth quarter. Blue Trust Inc. now owns 407 shares of the biotechnology company's stock valued at $56,000 after acquiring an additional 328 shares during the last quarter. GAMMA Investing LLC raised its stake in shares of Ascendis Pharma A/S by 58.0% in the fourth quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company's stock valued at $80,000 after acquiring an additional 214 shares during the period. Finally, Tower Research Capital LLC TRC lifted its holdings in shares of Ascendis Pharma A/S by 195.3% in the 4th quarter. Tower Research Capital LLC TRC now owns 1,004 shares of the biotechnology company's stock worth $138,000 after acquiring an additional 664 shares during the last quarter.

Analysts Set New Price Targets

A number of research firms recently weighed in on ASND. JPMorgan Chase & Co. increased their price objective on shares of Ascendis Pharma A/S from $200.00 to $245.00 and gave the stock an "overweight" rating in a research report on Friday, May 2nd. Evercore ISI raised their price target on Ascendis Pharma A/S from $260.00 to $280.00 and gave the stock an "outperform" rating in a research note on Friday, May 2nd. Cantor Fitzgerald upped their price objective on Ascendis Pharma A/S from $170.00 to $200.00 and gave the company an "overweight" rating in a research report on Tuesday, February 25th. Royal Bank of Canada lifted their target price on Ascendis Pharma A/S from $205.00 to $210.00 and gave the stock an "outperform" rating in a research report on Friday, May 2nd. Finally, Morgan Stanley upgraded shares of Ascendis Pharma A/S from an "equal weight" rating to an "overweight" rating and upped their price target for the stock from $180.00 to $250.00 in a report on Monday. One investment analyst has rated the stock with a hold rating and fifteen have issued a buy rating to the company. According to MarketBeat.com, Ascendis Pharma A/S has a consensus rating of "Moderate Buy" and a consensus target price of $216.07.

Ascendis Pharma A/S Trading Down 0.8 %

Shares of ASND traded down $1.35 during trading hours on Thursday, hitting $159.64. The company had a trading volume of 712,636 shares, compared to its average volume of 497,283. The company has a market capitalization of $9.73 billion, a PE ratio of -22.48 and a beta of 0.41. Ascendis Pharma A/S has a one year low of $111.09 and a one year high of $183.00. The company's fifty day moving average price is $155.96 and its two-hundred day moving average price is $141.00.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last posted its earnings results on Thursday, May 1st. The biotechnology company reported ($1.66) EPS for the quarter, missing analysts' consensus estimates of ($1.56) by ($0.10). The company had revenue of $123.97 million for the quarter, compared to the consensus estimate of $98.56 million. Analysts forecast that Ascendis Pharma A/S will post -4.34 earnings per share for the current year.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.